Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Ovid Therapeutics President and CEO Margaret A. Alexander reported two equity transactions. She received an employee stock option for 1,435,000 shares at an exercise price of $0.00, which will vest in 48 equal monthly installments starting on March 20, 2026, contingent on continued service.
Separately, she sold 11,656 shares of common stock at a weighted average price of $1.45 per share. According to the disclosure, this was a mandatory “sell to cover” transaction to satisfy statutory tax withholding from vesting restricted stock units, and is described as not a discretionary sale. After the sale, she directly owned 61,750 common shares and held the newly granted option for 1,435,000 shares.
Ovid Therapeutics Inc. director Stelios Papadopoulos received a grant of stock options covering 65,000 shares on February 26, 2026. These options have an exercise price of $0.00 per share, meaning they were awarded at no cost to him when granted.
The option grant will vest in full on February 26, 2027, provided he remains in continuous service with the company through that date. After this grant, he holds options on 65,000 shares directly, aligning his compensation more closely with the company’s future performance.
Ovid Therapeutics Inc. reported that director Jeremy M. Levin received a grant of employee stock options covering 957,000 shares of Ovid common stock. These options were awarded as a form of compensation, not through an open-market purchase or sale.
According to the terms, the options will vest in 48 equal monthly installments starting on March 20, 2026. Vesting is conditioned on Levin’s continued service to the company through each vesting date, meaning he earns the right to exercise a portion of the options each month over a four-year period.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald reported receiving an employee stock option grant covering 65,000 shares of common stock. The option was awarded on February 26, 2026 and is scheduled to vest in full on February 26, 2027, provided he remains in continuous service through that date.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Bart Friedman reported receiving an equity award in the form of an employee stock option covering 65,000 shares. The option was granted at no cost on February 26, 2026 and will vest in full on February 26, 2027, provided he remains in continuous service through that date.
DUNCAN BARBARA GAYLE reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Barbara Gayle Duncan received a grant of employee stock options covering 65,000 shares on February 26, 2026. The options have a stated price of $0.0000 per share and will vest in full on February 26, 2027, subject to her continuous service through that vesting date.
Bernstein Karen reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Karen Bernstein was granted employee stock options covering 65,000 shares of Ovid common stock. The award was made on February 26, 2026 and is reported at a grant price of $0.00 per share in this filing.
According to the terms, the option will vest in full on February 26, 2027, as long as Bernstein continues to provide service to the company through that date. After vesting, the option will become exercisable for the underlying shares, subject to the company’s equity plan and any applicable restrictions.
Ovid Therapeutics Inc. chief business and financial officer Rona Jeffrey reported a mix of equity grants and a small tax-related sale. On February 26, 2026, Jeffrey received an option to purchase 408,750 shares of Common Stock and a grant of 68,125 shares of Common Stock as a restricted stock unit award, both at a price per share of $0.00. The RSUs vest in three equal annual installments beginning February 20, 2027, and the stock options vest in 48 equal monthly installments beginning March 20, 2026, conditioned on continued service.
On February 23, 2026, Jeffrey sold 8,541 shares of Common Stock at a weighted average price of $1.45 per share. According to the disclosure, this sale was a mandatory “sell to cover” transaction to satisfy statutory tax withholding obligations triggered by restricted stock unit vesting, not a discretionary sale decision.
Ovid Therapeutics Inc. Schedule 13G discloses that ADAR1-related parties report beneficial ownership of 9,284,166 shares of Common Stock, equal to 6.9% of the class. The filing attributes these holdings to ADAR1 Capital Management, ADAR1 Capital Management GP and Daniel Schneeberger and ties the percentage to December 15, 2025, based on 130,184,353 shares outstanding reported in the issuer's prospectus.
Ovid Therapeutics Inc. received an updated ownership report from Affinity Asset Advisors, LLC and Michael Cho. The reporting persons beneficially own 12,149,166 shares of Ovid common stock, including 4,999,166 shares issuable upon exercise of warrants, representing approximately 9.0% of the outstanding common stock.
The securities are held through Affinity Healthcare Fund, LP, over which Affinity Asset Advisors acts as investment manager and Michael Cho is the managing member. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid.